One agonistic antibody target that showed very promising results in pre-clinical studies in mouse models of cancer and autoimmunity is CD137, which is mainly expressed on activated T cells, monocytes, and NK cells (29–31). This evidence concerns the gene TNFRSF9 and cancer.